Orchard Therapeutics PLC
Batika Rana has extensive experience in the field of scientific research, holding various roles at Orchard Therapeutics and Medical Research Council. At Orchard Therapeutics, they worked as a Senior Scientist/Associate in R&D from January 2019 to June 2021, then moved on to the role of Senior Scientist in Analytical from June 2021 to December 2022. Currently, they hold the position of Principal Scientist at Orchard Therapeutics. Prior to their work at Orchard Therapeutics, Batika worked at the Medical Research Council as a Career Development Fellow from an unspecified start date in 2014 to 2017, and later as an Investigator Scientist from 2017 to 2019.
Batika Rana completed a Bachelor of Science degree in Immunology at the University of Glasgow from 2005 to 2009. Batika then pursued a Master of Science degree in Immunology at King's College London from 2009 to 2010. Finally, they obtained their Doctor of Philosophy (PhD) in Immunology from King's College London from 2010 to 2013.
This person is not in any offices
Orchard Therapeutics PLC
3 followers
Orchard Therapeutics plc, formerly Orchard Rx Ltd, is a commercial-stage, fully-integrated biopharmaceutical company. It is engaged in manufacturing and commercialization of gene and cell therapies, position to provide transformative therapies to patients suffering from a range of rare diseases. The Company is focused on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders and hemoglobinopathies. Its portfolio includes Strimvelis, its commercial-stage gammaretroviral-based product for the treatment of ADA-SCID five lentiviral product candidates in clinical-stage development and several other product candidates in preclinical development. It is developing OTL-101 as an autologous ex vivo lentiviral gene therapy to sustainably treat patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID) through a single administration.